Fear Conditioning Using Computer-Generated Virtual Reality

The purpose of this study is to use a computer-generated virtual reality environment to study fear conditioning. Fear conditioning is used to explore the causes and persistence of anxiety and anxiety disorders.

When confronted with fearful or unpleasant events, people can develop fear of specific cues that were associated with these events as well as to the environmental context in which the events occurred via a process called classical or aversive conditioning. Advances in computer-generated visual stimulations could facilitate the design of new aversive conditioning studies. This study will develop a virtual reality environment to examine human contextual fear conditioning in the laboratory. During the procedure, moderately painful stimuli will be administered. Participants in this study will be screened with a medical history, physical examination, psychiatric evaluation, and hearing test. Participants will wear headphones and special goggles that will enable them to view a virtual reality environment. Measures will be taken during the study to see how the brain adapts to environmental stimuli.

Study Overview

Status

Completed

Conditions

Detailed Description

Fear conditioning paradigms are tools to explore symptoms of anxiety disorders. During fear conditioning, the organism develops fear to the phasic explicit cue (e.g., a light) that was associated with the aversive unconditioned stimulus (e.g., a shock) during conditioning as well as to the environmental context (e.g., the experimental room). Explicit cue conditioning and context conditioning are separate processes mediated by distinct brain structures. Whereas explicit cue conditioning is only dependent on the amygdala, context conditioning involves the amygdala, the hippocampus and the bed nucleus of the stria terminalis (BNST). We have been using explicit cue and context conditioning as models of phasic fear and sustained anxiety, respectively. However, contextual fear is relatively difficult to study in humans in the laboratory because it requires two experimental sessions and the use of different experimental rooms. Advances in computer-generated visual stimulation now offer the possibility to develop more sophisticated paradigms in the laboratory that could facilitate the design of fear conditioning studies. In addition, compared to traditional paradigms, computer generated three-dimensional stimulation provides the opportunity to create more realistic virtual environment. The main objective of this study is to use virtual reality to further our understanding of fear conditioning in humans.

Study Type

Observational

Enrollment (Actual)

202

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Maryland
      • Bethesda, Maryland, United States, 20892
        • National Institutes of Health Clinical Center, 9000 Rockville Pike

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

7 years to 50 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

  • INCLUSION CRITERIA:

Subjects will be healthy volunteers ages 7-50 recruited through advertisements in the local media.

Subjects will be free of current or past psychotic disorder and organic central nervous system disorders.

All children will be screened for lifetime history of psychiatric disorders using the K-SADS Interview. The interview will be administered by a trained clinician (at least master level) supervised by Dr. Pine.

The children/adolescents will be able to give assent and parents will give consent.

They will have an IQ greater than 70 based on WASI.

EXCLUSION CRITERIA:

Ongoing medical illness that could interfere with the study

Current psychiatric or neurological disorder (including seizure)

Past psychotic disorder

Current substance abuse

Current psychotropic medication

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 22, 2001

Study Completion

April 10, 2012

Study Registration Dates

First Submitted

October 26, 2001

First Submitted That Met QC Criteria

October 26, 2001

First Posted (Estimate)

October 28, 2001

Study Record Updates

Last Update Posted (Actual)

July 2, 2017

Last Update Submitted That Met QC Criteria

June 30, 2017

Last Verified

April 10, 2012

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anxiety Disorder

3
Subscribe